Identification of Hepatic Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

218 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-04-30

Study Completion Date

2003-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions

NCT07055048

Liver Cancer, Adult

NOT_YET_RECRUITING

PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma

NCT05580835

Carcinoma, Hepatocellular

UNKNOWN NA

Radiomics for Diagnosing Liver Diseases and Evaluating Progression

NCT03221049

Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation

UNKNOWN

Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility

NCT03342677

Hepatocellular Carcinoma

UNKNOWN NA

Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction

NCT07108725

Non-invasive Diffusion-weighted Imaging Magnetic Resonance Cholangiopancreatography Diagnosis +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Group Type EXPERIMENTAL

Resovist (BAY86-4884, SH U 555 A)

Intervention Type PROCEDURE

Single bolus injection, followed by MRI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resovist (BAY86-4884, SH U 555 A)

Single bolus injection, followed by MRI

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Present with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment. There should not be more than five liver lesions on type visualized on CT.

The patient should be in a condition that allows subsequent treatment.
2. Be willing and able to continue study participation following administration of SH U 555 A to ensure completion of all procedures and observations required by the trial protocol.
3. Sign and date fully informed consent prior to entry into the study.

Exclusion Criteria

* Patients under 18 years of age.
* Patients weighing less than 35 kg.
* Patients who have received any investigational drug within the 30 days prior to entering this study.
* Patients who have previously entered this study or any other study performed with SH U 555 A.
* Women who are pregnant or who are of childbearing potential and have not had a negative urine pregnancy test immediately prior to the administration of SH U 555 A. The urine pregnancy test should be performed in accordance with the manufacturer's recommendations.
* Lactating women.
* Patients who have any contraindication to MRI examination.
* Patients who have received any contrast material in the 24 hours prior to SH U 555 A injection, or who are scheduled to receive any contrast material within 24 hours afterwards. (In the case of any liver specific agent (e.g. MnDPDP, SPIOs, Gd-BOPTA) this will be extended to 14 days prior to the study).
* Patients who have received Lipiodol contrast material at any time in the past or are scheduled to receive this during the study period.
* Patients who are clinically unstable and whose clinical course during the observation period is unpredictable (e.g. due to previous surgery).
* Patients scheduled for liver biopsy within 24 hours, or who had a biopsy within the 24 hours prior to planned SH U 555 A injection.
* Patients who are scheduled for, or are likely to require, surgery within 24 hours after SH U 555 A injection.
* Patients with a history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents.
* Patients with known hypersensitivity to any of the ingredients of SH U 555 A.
* Patients with already clear op-indication

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No